{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 457130773
| IUPAC_name = Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate
| image = Anileridine2DCSD.svg
| width = 150px
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|monograph|buprenorphine-hydrochloride}}
| pregnancy_category =  
| legal_AU = S8
| legal_CA = Schedule I
| legal_US = Schedule II
| legal_DE = Anlage I
| routes_of_administration = Tablets, injection
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = > 95%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life =  
<!--Identifiers-->
| IUPHAR_ligand = 7115
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 144-14-9
| ATC_prefix = N01
| ATC_suffix = AH05
| ATC_supplemental =  
| PubChem = 8944
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00913
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8600
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 71Q1A3O279
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02941
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 61203
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201347
<!--Chemical data-->
| C=22 | H=28
| N=2 | O=2
| molecular_weight = 352.47 g/mol
| smiles = O=C(OCC)C3(c1ccccc1)CCN(CCc2ccc(N)cc2)CC3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = LKYQLAWMNBFNJT-UHFFFAOYSA-N
| melting_point = 83
}}

'''Anileridine''' (trade name: '''Leritine''') is a synthetic [[analgesic]] drug and is a member of the [[piperidine]] class of analgesic agents developed by Merck & Co. in the 1950s.<ref>{{US Patent|2897204}}</ref> It differs from [[pethidine]] (meperidine) in that the ''N''-methyl group of meperidine is replaced by an ''N''-aminophenethyl group, which increases its analgesic activity.

Anileridine is no longer manufactured in the US or Canada.<ref>{{Cite web |last= |first= |title=Discontinued Prescription Drug Products |publisher=Canadian Pharmacists' Association |date= |url=http://www.pharmacists.ca/content/hcp/tools/drugnews/discontinued.htm |accessdate=28 July 2008}}</ref>  Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014.  The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate <ref>http://www.deadiversion.usdoj.gov/fed_regs/quotas/2014/fr0825.htm</ref>  It is also under international control per UN treaties.

==Administration==
As [[Tablet (pharmacy)|tablets]] or [[Injection (medicine)|injection]].<ref>{{Cite web |last= |first= |title=Pharmaceutical Information - LERITINE |publisher=RxMed |date= |url=http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20%28General%20Monographs-%20L%29/LERITINE.html |accessdate=16 June 2010 }}</ref>

==Pharmacokinetics==
Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2â€“3 hours.<ref>{{Cite web |last= |first= |title=Anileridine Consumer Information |publisher=MedicineNet |date= |url=http://www.medicinenet.com/anileridine-oral_tablet/article.htm |accessdate=28 July 2008}}</ref>  It is mostly metabolized by the [[liver]].
==References==
{{Reflist|2}}


{{Analgesics}}
{{General anesthetics}}
{{Opioidergics}}

[[Category:Piperidines]]
[[Category:Synthetic opioids]]
[[Category:General anesthetics]]
[[Category:Anilines]]
[[Category:Ethyl esters]]
[[Category:Mu-opioid agonists]]
[[Category:Analgesics]]


{{nervous-system-drug-stub}}